Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia 23Lymphoma 21Leukemia, Myeloid, Acute 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Myelodysplastic Syndromes 13Multiple Myeloma 13Breast Neoplasms 13Ovarian Neoplasms 11Lymphoma, Follicular 10Lymphoma, Mantle-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Leukemia, Biphenotypic, Acute 9Hodgkin Disease 9Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Sarcoma 7Waldenstrom Macroglobulinemia 6Burkitt Lymphoma 6Testicular Neoplasms 5Testicular Germ Cell Tumor 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myelomonocytic, Chronic 5Carcinoma, Ovarian Epithelial 5Blast Crisis 5Myeloproliferative Disorders 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Congenital Abnormalities 4Central Nervous System Neoplasms 4

Interventions

Dexamethasone 4fludarabine 2daratumumab 2Lenalidomide 2Bortezomib 2Alemtuzumab 2pomalidomide 1nirogacestat 1filanesib 1Tacrolimus 1Steroids 1Stem Cell Transplantation 1KW-2478 1Injections, Subcutaneous 1Hsp90 inhibitor KU757 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Busulfan 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Paraproteinemias × Filgrastim × Clear all
NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡